Compare Ferrari NV (RACE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Sana Biotechnology Inc — how do they compare? Ferrari NV trades at $389.91 (market cap $67.35B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Ferrari NV is far larger — about 80.5× Sana Biotechnology Inc's market cap, and Ferrari NV pays a 1.09% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Sana Biotechnology Inc for 23 Days on average.
| RACE | SANA | |
|---|---|---|
Market Cap | $67.35B | $836.71M |
Volume | 390,618 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $5.92 |
52-Week Low | $314.63 | $2.68 |
Typical Hold Time | 126 Days | 23 Days |
Enterprise Value | $69.22B | $749.96M |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $388.77, up 0.62% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15 billion in 2025, and net income margin remains robust at 22.25%. The company is executing a share buyback program and expanding partnerships, such as with Rakuten effective 2027.
The outlook is positive given analyst consensus of $462.75 price target and 73.69% buy ratings. Risks include high valuation multiples and exposure to economic cycles. Institutional interest is rising, but technical indicators suggest near-term resistance at $390.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
